Takayasu Arteritis Clinical Trials

12 recruiting

Takayasu Arteritis Trials at a Glance

16 actively recruiting trials for takayasu arteritis are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 4 with 4 trials, with the heaviest enrollment activity in Shanghai, Edinburgh, and Beijing. Lead sponsors running takayasu arteritis studies include Shanghai Zhongshan Hospital, Marmara University, and University of Edinburgh.

Browse takayasu arteritis trials by phase

Treatments under study

About Takayasu Arteritis Clinical Trials

Looking for clinical trials for Takayasu Arteritis? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Takayasu Arteritis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Takayasu Arteritis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting

Global Initiative on Takayasu Arteritis (GITA)

Takayasu's ArteritisTakayasu Arteritis (TAK)
Marmara University1,000 enrolled2 locationsNCT07558382
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Not Applicable

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

Takayasu Arteritis
Marmara University40 enrolled1 locationNCT07491913
Recruiting

VCRC Tissue Repository

Microscopic PolyangiitisGiant Cell ArteritisTakayasu Arteritis+8 more
University of Pennsylvania1,000 enrolled8 locationsNCT02967068
Recruiting

Vasculitis Pregnancy Registry

Behcet's DiseaseVasculitisCNS Vasculitis+12 more
University of Pennsylvania100 enrolled1 locationNCT02593565
Recruiting
Phase 2

Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)

Giant Cell Arteritis (GCA)Takayasu ArteritisLarge Vessel Vasculitis
University of Edinburgh60 enrolled1 locationNCT06887062
Recruiting

Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis

Takayasu ArteritisTakayasu Arteritis (TAK)
University of Edinburgh50 enrolled1 locationNCT07351422
Recruiting

Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Controls

Takayasu ArteritisBehçet's Disease
ÖZLEM NUR TOK YAMAN30 enrolled1 locationNCT07276087
Recruiting

Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement

Takayasu Arteritis With Pulmonary Artery InvolvementPulmonary Arterial Hypertension Associated With Connective Tissue Disease
China-Japan Friendship Hospital150 enrolled1 locationNCT07184814
Recruiting

Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases

Rheumatoid ArthritisCeliac DiseaseSjogren's Syndrome+6 more
Santé Arménie French-Armenian Research Center800 enrolled6 locationsNCT05904301
Recruiting
Phase 4

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

Takayasu Arteritis
Shanghai Zhongshan Hospital124 enrolled1 locationNCT06498089
Recruiting
Phase 4

Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

Takayasu Arteritis
Shanghai Zhongshan Hospital76 enrolled1 locationNCT05102448
Recruiting
Not Applicable

Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)

Cerebral IschemiaTakayasu Arteritis
Xuanwu Hospital, Beijing44 enrolled1 locationNCT06178419
Recruiting

Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement

Takayasu Arteritis With Pulmonary Artery InvolvementPercutaneous Transluminal Pulmonary AngioplastyPAH Targeted Medication
Chinese Pulmonary Vascular Disease Research Group200 enrolled1 locationNCT05388682
Recruiting

The Registry Study of Takayasu Arteritis in East China

Treatment RefusalPregnancy RelatedTakayasu Arteritis+2 more
Shanghai Zhongshan Hospital1,000 enrolled1 locationNCT03893136
Recruiting
Phase 4

A Pilot Study in Severe Patients With Takayasu Arteritis.

TreatmentTakayasu ArteritisTocilizumab+1 more
Shanghai Zhongshan Hospital40 enrolled1 locationNCT04300686